Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue was approximately RMB 784.8 million, an increase of about RMB 58.5 million or 8.1% compared to RMB 726.3 million for the fiscal year ending December 31, 2024[3]. - The gross profit for the fiscal year ending December 31, 2025, was approximately RMB 562.4 million, an increase of about RMB 19.7 million or 3.6% compared to RMB 542.7 million for the fiscal year ending December 31, 2024[5]. - The company reported a profit before tax of RMB 7.1 million for the fiscal year ending December 31, 2025, a significant decrease from RMB 73.2 million for the fiscal year ending December 31, 2024[8]. - The total comprehensive income for the fiscal year ending December 31, 2025, was RMB 6.9 million, down from RMB 73.1 million for the fiscal year ending December 31, 2024[8]. - The net profit for the year ended December 31, 2025, was RMB 7.1 million, a significant decrease from RMB 73.2 million for the year ended December 31, 2024[125]. - Other income and gains totaled approximately RMB 15.5 million for the year ended December 31, 2025, a significant decrease from RMB 45.1 million in 2024[118]. Cost and Expenses - The cost of sales increased from RMB 183.7 million for the fiscal year ending December 31, 2024, to approximately RMB 222.4 million for the fiscal year ending December 31, 2025, representing about 28.3% of total revenue for the same year (2024: 25.3%) [4]. - Sales and distribution expenses rose to RMB 340.9 million for the fiscal year ending December 31, 2025, up from RMB 285.8 million for the fiscal year ending December 31, 2024, marking a 19.3% increase[6]. - Research and development expenses for the fiscal year ending December 31, 2025, were approximately RMB 147.6 million, a decrease of about RMB 1.7 million compared to RMB 149.3 million for the fiscal year ending December 31, 2024[7]. - Financial costs totaled RMB 38,658 thousand in 2025, up from RMB 32,651 thousand in 2024, marking an increase of 18.4%[30]. - Administrative expenses decreased from RMB 46.5 million for the year ended December 31, 2024, to RMB 41.2 million for the year ended December 31, 2025, due to improved management measures[120]. Assets and Liabilities - Non-current assets increased to RMB 2,112,330 thousand in 2025 from RMB 1,895,008 thousand in 2024, representing an increase of approximately 11.5%[9]. - Current assets rose significantly to RMB 2,013,310 thousand in 2025, up from RMB 956,280 thousand in 2024, marking an increase of approximately 110.9%[9]. - Total liabilities decreased to RMB 1,385,753 thousand in 2025 from RMB 1,297,250 thousand in 2024, a reduction of about 6.8%[10]. - Net assets increased to RMB 2,739,887 thousand in 2025, compared to RMB 1,644,038 thousand in 2024, reflecting a growth of approximately 66.6%[10]. - The company reported cash and cash equivalents of RMB 1,130,402 thousand in 2025, a significant increase from RMB 198,867 thousand in 2024, representing a growth of approximately 468.5%[9]. Market and Product Development - The company has commercialized five products during the reporting period, contributing to rapid revenue growth[3]. - The company has established a professional commercialization team to strengthen its market position domestically, laying a solid foundation for future transformation[3]. - The company has five approved products and is developing biopharmaceutical products in markets including the USA, EU, UK, and Japan[58]. - The company focuses on multiple therapeutic areas including oncology, autoimmune diseases, ophthalmology, and metabolic diseases[57]. - The company has a balanced product pipeline with five approved products and eight candidates in various clinical trial stages, focusing on oncology, metabolism, autoimmune, and ophthalmology[65]. Research and Development - The company continues to strengthen its R&D capabilities with a team of 245 experienced employees across various research functions[61]. - The company has a proprietary R&D platform focused on antibody discovery and drug development, with facilities in Yantai, Nanjing, and Boston[93]. - The company has filed multiple patent applications globally, with 53 patents granted and 43 pending as of the announcement date[96]. - The company has established strong CMC capabilities, ensuring high quality and cost efficiency throughout the drug development and commercialization process[94]. Strategic Partnerships and Collaborations - The company has entered into a strategic partnership with DeepMind Technology to build an AI-driven innovation model as of March 2026[63]. - The company is actively discussing licensing or co-development of its innovative drug pipeline with several pharmaceutical companies and investment institutions[106]. - The company is collaborating with various well-resourced business partners to enhance its market presence and product accessibility[104]. Corporate Governance - The revised corporate governance code will take effect on July 1, 2025, and will apply to the company's corporate governance report and annual report for fiscal years starting on or after this date[144]. - The company has established appropriate checks and balances regarding the dual role of the Chairman and CEO, held by Ms. Jiang Hua, who has extensive experience in the pharmaceutical industry[145]. - The company has adopted a set of conduct rules for directors regarding securities trading, which meet or exceed the standards set forth in the listing rules[146].
博安生物(06955) - 2025 - 年度业绩